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Abstract
Background: Current real-time PCR-based HIV-1 viral load (VL) assays allow the detection of residual viraemia in
antiretroviral-treated patients. The clinical outcome of HIV-1 patients experiencing low-level replication (<50 cop/mL) in
comparison with fully suppressed patients is currently debated. We analysed variability of 3 VL assays <50 cop/mL, and
evaluated the reproducibility of viral blips <100 cop/mL.
Methods: Three commercial VL assays were tested: Versant HIV-1 RNA 1.0 kPCR (Siemens), Abbott Realtime HIV-1, and
Cobas Ampliprep/Cobas Taqman HIV-1 v2.0 (Roche). Ten replicates of a reference sample at 4 low target dilutions were
tested to evaluate assay variability. Prospective collection of 181 clinical samples with detectable VL <50 cop/mL was
used to evaluate intra-and inter-assay variability by triplicate testing. Samples from 26 patients experiencing a viral blip
were retested.
Results: All assays showed substantial variability at low VL level: the coefficient of variation at 100, 50, 25 and 12 cop/mL
ranged respectively from 32 to 44%, 35 to 68%, 41 to 83% and 33 to 77%. In the intra-assay evaluation of repeatability,
52.5 to 57.5% of detectable VL <50 cop/mL tested in triplicate showed at least one fully undetected result. Variability
was similar in the inter-assay arm. The VL blips could only be reproduced in 19% of cases.
Conclusions: The most recent versions of widespread commercial VL assays showed substantial variability at low levels
and residual viraemia could not be consistently reproduced. Patient outcome studies comparing residual VL to full
suppression are therefore biased when using commercial assays.
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Background
Plasma viral load (VL) measurements are part of the rou-
tine follow-up for patients infected with HIV [1,2]. Anti-
retroviral therapy (ART) aims to block viral replication,
leading to plasma viraemia below the clinically validated
threshold of 50 copies per millilitre (cop/mL) of plasma.
Below this limit, the patient has the lowest morbidity
and mortality probabilities [3]. However, this threshold
of 50 cop/mL reflects the performance characteristics of
VL assays available before the launch of real-time PCR-
based assays, which allow the detection of low numbers
of RNA copies present in the sample.
The limit of detection (LoD) does not usually equal the
lower limit of quantification (LLoQ) at which the error
meets the requirements for reproducibility and linearity
[4]. Under the linear range, variability is unacceptably
high and accurate quantification remains elusive [5,6].
Nonetheless, recent VL assays report qualitative results
below LLoQ as detected or not detected, suggesting the
presence or absence of residual viraemia.
The cause and the consequence of low VL are currently
investigated [7]: HIV RNA can originate from the release
of virus from the reservoirs or from residual replication
[8]. Using modified protocols of commercial assays or in-
house assays to monitor VL, intensification of ART in
patients with incompletely suppressed VL bore no result
[9], and low-level viraemia was not associated with
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suboptimal CD4 gains during therapy [10]. Comparisons
of drug efficacy on residual viraemia showed favourable
profile for fixed-dose combinations including efavirenz
[11], although others showed superior outcome when
using nevirapine instead of efavirenz [12]. Some studies
suggest that residual viraemia is predictive of future
treatment failure [13], whilst some suggest no further
effect [14]. We hypothesised that those results could
not be translated to routine settings because they ex-
ceed the technical abilities of current commercial real-
time PCR assays. We evaluated the variability of 3
commercial real-time HIV-1 VL assays on samples with
detectable VL but <50 cop/mL, and analysed the re-
peatability of low-level viraemia in clinical routine set-
tings in order to demonstrate the hypothesis.
Results
Dilutions of a reference sample
The descriptive statistics and the number of undetected
samples are illustrated in Table 1. No signal was detected
for any of the HIV-negative samples or negative kit con-
trols throughout the study with any of the assays.
As noted during the preparation of the reference sam-
ple, the absolute quantification was the highest for the
CAP/CTM v2.0, and the lowest for the kPCR that quali-
fied 30% of the 100 cop/mL samples as detected below
its LLoQ. At the target dilution of 12 cop/mL, the
Abbott Realtime HIV-1 assay showed the highest rate of
undetected samples with 70% of negative results while
the others had 20% in comparison. Variability was the
highest for CAP/CTM v2.0: the CV ranged from 33 to
83%, while the CV of kPCR and Realtime assays varied
respectively from 42 to 48%, and from 32 to 68%. Of
note, CAP/CTM v2.0 has the highest variability at the 25
cop/mL target and failed to detect one sample at a value
theoretically above its LLoQ of 20, although below the
LLoQ of the comparators. The distribution of values at
each concentration is shown on Figure 1. Based on this
set of results, the LoDs inferred by Pobit analysis were
14.76, 18.89 and 23.19 cop/mL respectively for the kPCR,
Abbott realtime and CAP/CTM v2.0, limit defined as the
RNA concentration detected with 95% or greater
probability.
Clinical samples
The variability was tested on 181 clinical samples
obtained from patients experiencing residual viraemia
<50 cop/mL. As samples had been selected prospectively
and consecutively, with the only criterion defined as a
detectable VL <50 cop/mL, we checked if the viral sub-
type was representative for our population. A genotype
was available for 61.2% of the patients. The clade preva-
lence in our cohort was similar to the Belgian HIV-1
population, the most abundant ones being subtype B,
CRF02, A1 and C: respectively 47, 14, 14 and 10% of the
patients.
Table 2 details the number of samples with discord-
ant results between triplicates. All assays behaved
similarly to over 50% of samples where at least one
replicate was not detected. Between 2.5 and 5% of the
samples had one replicate >100 cop/mL. Figure 2
details the distribution of the 61 samples tested by in-
ter-assay comparison, as well as the distribution of 40
triplicates for each method in the intra-assay evalu-
ation: variability is the cause of frequent results above
the threshold of 50 cop/mL, as well as undetected
ones.
Viral blips
Medical records were examined and 26 cases corre-
sponding to our blip definition (between 50 and 100
cop/mL) were re-analysed. Patients experiencing those
blips represented between 1 and 1.5% of the population
followed in the participating centres. The VL sequence
of the blips, i.e. a VL <50 cop/mL followed by a value
between 50 and 100 cop/mL going back afterwards <50,
could only be reproduced in 5 cases (19.2%). In the
remaining 21 cases, 16 were detected below 50 cop/mL
and 5 were not detected. All samples preceding and fol-
lowing the putative blip gave a <50 cop/mL result again,
except for one case where the value before the blip and
the blip itself were respectively 62 and 64 cop/mL.
Table 1 Descriptive statistics related to 10 replicates of a
reference sample at four target dilutions
Siemens Abbott Roche
100 cop/ml Mean (cop/mL) 60.6 84.5 115.4
SD (cop/mL) 26.7 27.7 38.3
CV (%) 44.0 32.8 33.2
Undetected (%) 0 0 0
50 cop/ml Mean (cop/mL) 35.3 33 65.8
SD (cop/mL) 15.3 22.5 22.7
CV (%) 43.2 68.1 34.5
Undetected (%) 0 0 0
25 cop/ml Mean (cop/mL) 18.1 25.5 26.56
SD (cop/mL) 8.7 10.4 22.1
CV (%) 48.1 40.7 83.1
Undetected (%) 0 0 10
12 cop/ml Mean (cop/mL) 15.6 20.0 25.8
SD (cop/mL) 6.6 6.6 19.9
CV (%) 42.2 32.8 77.1
Undetected (%) 20 70 20
Undetected samples were censored from the calculations. Siemens = Versant
HIV-1 RNA 1.0 kPCR (Siemens), Abbott = Realtime HIV-1 (Abbott), Roche =Cobas
Ampliprep/Cobas Taqman HIV-1 v2.0 (Roche), SD: standard deviation,
CV: coefficient of variation.
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Discussion
Variability of three commercial HIV-1 VL assays was
investigated at low values below the clinical cut-off of
50 cop/mL.
As all the assays tested used automated platforms for
viral RNA extraction and PCR reactive handling, no dis-
crepancies due to human interference are to be consid-
ered. Moreover, the samples underwent no additional
thaw and freeze cycle. Depending on the assay, variability
at 50 cop/mL rose from 34 to 68% (CV) when a refer-
ence sample was diluted in human HIV-negative plasma:
results round that cut-off are therefore uncertain, mak-
ing a precise estimation of values just above 50 cop/mL
difficult. Even at the 100 cop/mL target, 30% of samples
were quantified<LLoQ with the kPCR assay. When
focussing on lower values, variability was the highest
with the CAP/CTM v2.0 assay. The latter missed 1 out
of 10 replicates above its LLoQ. The Abbott Realtime
Figure 1 Low-level VL variability evaluated with a reference sample. Box Plot showing the distribution of 10 replicates of a reference
sample at four dilutions (100, 50, 25 and 12 cop/ml or 2, 1.7, 1.4 and 1.1 log cop/ml) tested on each platform. The bottom and the top of the box
represent the lower and the upper quartiles respectively. The triangle in the box is the median, and the ends of the whiskers correspond to the
minimum and the maximum values. Siemens = Versant HIV-1 RNA 1.0 kPCR (Siemens), Abbott = Realtime HIV-1 (Abbott), Roche= Cobas
Ampliprep/Cobas Taqman HIV-1 v2.0 (Roche).



























Intra-assay Siemens (N = 40) 52.5 32.5 2.5 2.5 0.0
Intra-assay Abbott(N = 40) 57.5 20.0 15.0 5.0 0.0
Intra-assay Roche(N= 40) 55.0 20.0 12.5 2.5 0.0
Inter-assay(N= 61) 52.5 13.1 18.0 4.9 3.3
Each sample was tested in triplicate, the first replicate being detected but quantified below 50 cop/mL. Siemens = Versant HIV-1 RNA 1.0 kPCR (Siemens),
Abbott = Realtime HIV-1 (Abbott), Roche = Cobas Ampliprep/Cobas Taqman HIV-1 v2.0 (Roche).
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HIV-1 assay seemed less sensitive than the others at
the 12 cop/mL level, although the LoDs inferred from
our results are similar with the 3 assays, ranging from
15 to 23 cop/mL.
Repeatability of RNA detection <50 cop/mL was eval-
uated on 181 triplicates, either intra- or inter-assay: more
than 50% of results cannot be reproduced on the 3
aliquots.
Those observations are in line with the PCR limits, as
well as with the limits given by the assay manufacturers:
every PCR will lead to stochastic results when targets
introduced in the reaction mixture lie between the limit
of blank and the limit of detection [4], and companies
define their own assay lowest LLoQ level below which
the results cannot be treated in a quantitative manner.
Extreme values cannot be reproduced quantitatively and
are therefore considered as “lower than LLoQ” in clinical
practice.
The results below the LLoQ are reported as detected
or not detected by the assays software, and such infor-
mation should not be reported to the clinician because
of uncertainty. This distinction between the presence
and absence of PCR signal, together with the launch of
assays with LoQ below 50 cop/mL, led to the notion that
some patients previously considered as therapy-controlled
undergo low-level viraemia, and that others are fully sup-
pressed, i.e. no viral genome can be detected in the
plasma. Studies investigating patient outcome when re-
sidual viraemia is detected were published, as well as in-
tensification trials exploring the effect of an additional
antiretroviral drug on full viral suppression. Some authors
used methodology enabling to concentrate the HIV-1
RNA by extracting from 4 mL up to 30 mL of plasma fol-
lowing ultracentrifugation [15-17], or repeat the test 3
times [18], lowering the detection limits of PCR and redu-
cing the variability in the low copy number range. Those
modified assays may be useful to answer scientific ques-
tions about low-level viraemia, but cannot be translated
into clinical practice because the variability of most recent
versions of widespread commercial VL assays is too high.
Our study was not designed to study the assays’ speci-























































































































































































Figure 2 Repeatability of VL below 50 cop/ml in clinical settings. A. Inter-assay variability. The plasma VL of sixty-one samples were tested
with the assays from Siemens = Versant HIV-1 RNA 1.0 kPCR (Siemens), Abbott = Realtime HIV-1 (Abbott), Roche=Cobas Ampliprep/Cobas Taqman
HIV-1 v2.0 (Roche). B. Intra-assay repeatability on 40 triplicates tested with Versant HIV-1 RNA 1.0 kPCR (Siemens). C. Intra-assay repeatability on 40
triplicates tested with Realtime HIV-1 (Abbott). D. Intra-assay repeatability on 40 triplicates tested with Cobas Ampliprep/Cobas Taqman HIV-1
v2.0 (Roche).
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samples do not lead to false positive signal, as confirmed
here with 10 negative samples. Low values can indeed be
considered as true viraemia [19] but negative ones can-
not be considered as proof of full viral suppression. RNA
viral genomes can originate from long-living infected
cells producing viral particles in the absence of replica-
tion, or reflect a residual replication. Strategies aiming at
viral eradication need to target the source of circulating
viruses [20]. Whether this residual viraemia is the begin-
ning of virological failure is subject to debate [7,13,14].
We would suggest that current commercial real-time
PCR assays do not have sufficient precision to answer
this burning question. Variability in the low copy number
range has also implications both for the classification of
elite controllers as well as for diagnosis strategies using
molecular assays.
In the same way, outcome comparisons of different ART
regimens regarding full suppression must be powered
enough to take into account assay variability. Although the
samples used in this study were taken from patients on
suppressive ART, the population was not big enough to
detail the drug classes used in the subgroup of reprodu-
cible low VL versus the others.
Viral blips between 50 and 100 cop/mL were not
reproduced in 80% of the 26 cases. As analytical assay
variability is high around 50 cop/mL (Figure 1), it is
therefore useful in clinical practice to confirm the result
on a new sample to assess if viral replication is really in-
creasing: the samples following the blips tested here were
all repeatedly <50 cop/mL. Our results are in line with
the 2011 revision of the DHHS guidelines which define
the virological failure threshold as 200 cop/mL [1]. Con-
sequently, a single value between 50 and 200 cop/mL
should not be a reason enough for dropping a case out
of clinical studies.
Conclusions
In conclusion, state of the art VL assays tested here
showed poor reproducibility of HIV-1 low-level viraemia
results. When used in clinical routine settings with single
measurements, they introduce biases in patient outcome
studies comparing very low VL to full viral suppression.
Methods
Participating laboratories and assays
Three AIDS reference laboratories in Brussels accredited
by national legal bodies to either the EN-ISO 15189 or the
EN-ISO 17025 standard performed the analyses, one assay
running per site. The assays tested were Versant HIV-1
RNA 1.0 kPCR (Siemens, performed at UCLouvain, using
0.5 mL of plasma), Realtime HIV-1 (Abbott, performed at
Erasme using the 0.6 mL plasma volume protocol), and
Cobas Ampliprep/Cobas Taqman HIV-1 v2.0 (CAP/CTM,
Roche Diagnostics, perfomed at UZ Brussel, using 0.85 mL
of plasma). The manufacturers respectively report the
LLoQs as 37, 40 and 20 cop/mL. The volumes of plasma
mentioned are those actually extracted by the platforms,
excluding the dead volume linked to the pipetting steps.
Only a part of the RNA is introduced in the RT-PCR reac-
tion: respectively 79%, 56% and 67% of the total elution
volume, corresponding to 0.39, 0.33 and 0.57 mL of
plasma.
The manufacturers’ recommendations were strictly fol-
lowed and the same reagent lot was used throughout the
study, except for the re-evaluation of blips.
We did obtain quantitative results beyond the assays’
LLoQs using the Cq and the calibration curve and the
manufacturing companies offered some help when the
assay software did not produce a value in IVD conditions.
Dilutions of a reference sample
A reference HIV-1 sample, i.e. a culture supernatant dilu-
tion of a subtype B isolate, is routinely used in all of the
Belgian centres as an internal control in each VL run. We
assigned a “true” value to that reference sample based on
the results obtained in the last 25 VL runs per assay: the
mean VL ± SD was 3.13 ± 0.12 (Siemens), 3.18 ± 0.07
(Abbott) and 3.37 ± 0.08 log10 cop/mL (Roche). The
average value of 3.23 log10 cop/mL was used to prepare
aliquots of 100, 50, 25 and 12 cop/mL (2, 1.7, 1.4 and
1.1 log cop/mL) in commercial HIV-negative human
plasma (A&E Scientific, Belgium). Participating labora-
tories blind tested 10 aliquots of each dilution as well as
10 aliquots of the negative plasma used to prepare the
samples. The LoD was inferred by probit analysis using
the IBM SPSS Statistics 20 software.
Variability in patients with residual viraemia
The variability in clinical settings with patients experien-
cing residual viraemia below 50 cop/mL was assessed
with 181 samples. Each laboratory selected prospectively
and consecutively 62 plasma samples: when a fresh
whole EDTA blood sample was received for HIV-1 VL
testing, 3 aliquots were frozen and stored below −70°C.
If the first aliquot used for routine analysis gave a detect-
able result <50 cop/mL, the sample was included. Apart
from this condition and the availability of sufficient sam-
ple volume, no selection for the inclusion of samples was
made. Only one sample per patient was included. The
maximal duration of storage was limited to 6 weeks and
no additional freeze/thaw cycles were allowed. Forty
samples were tested in triplicate on the same platform
during different runs to assess the intra-assay variability,
and 22 others were shared with the 2 other laboratories
for an inter-assay evaluation. If one replicate gave an in-
valid result, the sample was excluded from the analysis: 61
samples were finally analysed in the inter-assay evaluation
whilst 5 were excluded because of failure of 1 replicate. The
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TRUGENE HIV-1 genotyping kit (Siemens, Tarrytown,
NY) determined the HIV-1 subtype based on the reverse
transcriptase sequence.
Viral blips
Laboratories searched their records to identify patients
who experienced a blip, i.e. a VL between 50 and 100
cop/mL during the follow-up and their previous and
next sample was <50 cop/mL, during the last 15 months.
The median time between the first and the second ana-
lysis was 7 months (ranging from 3 to 15), plasma sam-
ples being stored at −80°C. Twenty-six blips, together
with the previous and next sample from that patient,
were retested with the same assay and without additional
thaw and freeze cycle.
Abbreviations
VL: Viral load; ART: antiretroviral therapy; cop/mL: copies/mL; LoD: limit of
detection; LLoQ: lower limit of quantification; Cq: cycle of quantification;
CAP/CTM: Cobas Ampliprep/Cobas Taqman HIV-1 v2.0; CV: coefficient of
variation; IVD: in vitro diagnostic.
Competing interests
JR was invited twice as a speaker for Siemens Healthcare Diagnostics. The
other authors have declared no competing interests.
Authors’ contributions
JR initiated the study, centralised the data and drafted the manuscript. LD, EV
and ADB participated in the study design and helped to draft the
manuscript. MLD, DP and PG revised the design of the draft and provided
critical input. All authors read and approved the final manuscript.
Acknowledgements
The authors would like to acknowledge laboratory technicians Anita Wyns,
Veerle Bastiaensen and Linda Godau at the UZ Brussel, Isabelle Lefèvre, Najet
Lamarti and Philippe de Sany at the UCLouvain, and Maria-Helena Jurion,
Karin Miller and Nadine Gijbels at the Erasme Hospital.
The 3 companies involved in the present evaluation provided free kits, while
Abbott and Roche provided support to infer quantitative results under their
respective LLOQs.
Author details
1UCLouvain, AIDS Reference Laboratory, Avenue Hippocrate 54 - B1.54.05,
1200, Brussels, Belgium. 2Hôpital Universitaire Erasme, AIDS Reference
Laboratory, Route de Lennik 808, 1070, Brussels, Belgium. 3Vrije Universiteit
Brussel, AIDS Reference Laboratory, site Universitair Ziekenhuis Brussel,
Laarbeeklaan 101, 1090, Brussels, Belgium.
Received: 5 January 2012 Accepted: 24 April 2012
Published: 24 April 2012
References
1. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines
for the use of antiretroviral agents in HIV-1-infected adults and
adolescents. Department of Health and Human Services 1–239. Available at
http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
2. European AIDS Clinical Society Guidelines Version 6.0 [www.eacs.eu].
3. Cohen C: Low-level viremia in HIV-1 infection: consequences and implications
for switching to a new regimen. HIV Clin Trials 2009, 10:116–124.
4. Protocols for Determination of Limits of Detection and Limits of
Quantification. In Approved guideline NCCLS document EP17-A. NCCLS,
Wayne, Pennsylvania; 2004.
5. Paba P, Fabeni L, Ciccozzi M, Perno CF, Ciotti M: Performance evaluation of
the COBAS/TaqMan HIV-1 v2.0 in HIV-1 positive patients with low viral
load: a comparative study. J Virol Methods 2011, 173:399–402.
6. Yan CS, Hanafi I, Kelleher AD, Carr AD, Amin J, McNally LP, Cunningham PH:
Lack of correlation between three commercial platforms for the evaluation
of human immunodeficiency virus type 1 (HIV-1) viral load at the clinically
critical lower limit of quantification. J Clin Virol 2010, 49:249–253.
7. Pozniak A, Gupta RK, Pillay D, Arribas J, Hill A: Causes and consequences of
incomplete HIV RNA suppression in clinical trials. HIV Clin Trials 2009,
10:289–298.
8. Mavigner M, Delobel P, Cazabat M, Dubois M, L’Faqihi-Olive FE, Raymond S,
Pasquier C, Marchou B, Massip P, Izopet J: HIV-1 residual viremia correlates
with persistent T-cell activation in poor immunological responders to
combination antiretroviral therapy. PLoS One 2009, 4:e7658.
9. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, Kallungal B,
Palmer S, Medvik K, Lederman MM, et al: The effect of raltegravir
intensification on low-level residual viremia in HIV-infected patients on
antiretroviral therapy: a randomized controlled trial. PLoS Med 2010, 7:8.
10. Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, Hoh R, Lampiris H, Hunt PW,
Palmer S, McCune JM, et al: A randomized, controlled trial of raltegravir
intensification in antiretroviral-treated, HIV-infected patients with a
suboptimal CD4+ T cell response. J Infect Dis 2011, 203:960–968.
11. Rosso R, Di Biagio A, Maggiolo F, Nulvesu L, Callegaro AP, Taramasso L,
Bruzzone B, Viscoli C: Patient-reported outcomes and low-level residual
HIV-RNA in adolescents perinatally infected with HIV-1 after switching to
one-pill fixed-dose regimen. AIDS Care 2011, 24:54-58.
12. Haim-Boukobza S, Morand-Joubert L, Flandre P, Valin N, Fourati S, Sayon S,
Lavignon M, Simon A, Girard PM, Katlama C, et al: Higher efficacy of
nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1
copy/ml. AIDS 2011, 25:341–344.
13. Widdrington J, Payne B, Medhi M, Valappil M, Schmid ML: The significance
of very low-level viraemia detected by sensitive viral load assays in HIV
infected patients on HAART. J Infect 2011, 62:87–92.
14. Gianotti N, Galli L, Racca S, Salpietro S, Cossarini F, Spagnuolo V, Barda B,
Canducci F, Clementi M, Lazzarin A, Castagna A: Residual viraemia does
not influence 1 year virological rebound in HIV-infected patients with
HIV RNA persistently below 50 copies/mL. J Antimicrob Chemother 2011,
67:213-217.
15. Yukl SA, Li P, Fujimoto K, Lampiris H, Lu CM, Hare CB, Deeks SG, Liegler T,
Pandori M, Havlir DV, Wong JK: Modification of the Abbott RealTime assay
for detection of HIV-1 plasma RNA viral loads less than one copy per
milliliter. J Virol Methods 2011, 175:261–265.
16. Amendola A, Bloisi M, Marsella P, Sabatini R, Bibbo A, Angeletti C,
Capobianchi MR: Standardization and performance evaluation of
“modified” and “ultrasensitive” versions of the Abbott RealTime HIV-1
assay, adapted to quantify minimal residual viremia. J Clin Virol 2011,
52:17–22.
17. Anderson JA, Archin NM, Ince W, Parker D, Wiegand A, Coffin JM, Kuruc J,
Eron J, Swanstrom R, Margolis DM: Clonal sequences recovered from
plasma from patients with residual HIV-1 viremia and on intensified
antiretroviral therapy are identical to replicating viral RNAs recovered
from circulating resting CD4+ T cells. J Virol 2011, 85:5220–5223.
18. Mens H, Kearney M, Wiegand A, Spindler J, Maldarelli F, Mellors JW, Coffin
JM: Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals
with Viral Loads Below the Limit of Detection by Standard Clinical
Assays. J Vis Exp 2011, 55:e2960.
19. Verhofstede C, Van Wanzeele F, Reynaerts J, Mangelschots M, Plum J,
Fransen K: Viral load assay sensitivity and low level viremia in HAART
treated HIV patients. J Clin Virol 2010, 47:335–339.
20. Chun TW, Murray D, Justement JS, Hallahan CW, Moir S, Kovacs C, Fauci AS:
Relationship between residual plasma viremia and the size of HIV
proviral DNA reservoirs in infected individuals receiving effective
antiretroviral therapy. J Infect Dis 2011, 204:135–138.
doi:10.1186/1471-2334-12-100
Cite this article as: Ruelle et al: HIV-1 low-level viraemia assessed with 3
commercial real-time PCR assays show high variability. BMC Infectious
Diseases 2012, 12:100.
Ruelle et al. BMC Infectious Diseases 2012, 12:100 Page 6 of 6
http://www.biomedcentral.com/1471-2334/12/100
